Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
Date:12/10/2013

ALISO VIEJO, Calif., Dec. 10, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve-months ended September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues of $21.7 million
  • Gross and net NUEDEXTA® sales increased to $27.7 million and $20.2 million respectively
  • Cash, cash equivalents, and restricted investments of $57.5 million as of September 30, 2013
  • "2013 has been a break-out year for Avanir," said Keith A. Katkin, president and CEO of Avanir. "We have achieved a number of important and transformational milestones. In addition to robust growth of NUEDEXTA for PBA, we formed a co-promote partnership with Merck which will leverage our commercial leadership in the institutional setting. We also in-licensed a new investigational migraine treatment, gained European approval for NUEDEXTA and initiated a new phase II study of AVP-923 exploring its potential application in levadopa-induced dyskinesias in Parkinson's disease."

    Fiscal 2013 Fourth Quarter Results

  • Total net revenues for the quarter ended September 30, 2013 were $21.7 million, compared with $13.5 million for the comparable quarter in fiscal 2012, representing approximately 61% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses were $36.2 million in the fourth quarter of fiscal 2013, excluding a one-time payment of $20.0 million related to AVP-825, compared with $24.2 million in the comparable period in fiscal 2012.
  • Cash used in operations was $10.1 million, excluding a one-time payment of $20.0 million related to AVP-825.
  • Ne
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) ... of Understanding ("MOU") with LaurelCo, LLC, an Illinois ... of both cultivation and dispensary medical marijuana licenses in the ... MOU, GBLX will acquire a 20% equity interest in LaurelCo, ... TM growing chambers, as well as all technology related ...
    (Date:7/25/2014)... 25, 2014  Solanbridge Group Inc (OTC: SLNX) is ... interest in Buzznbrewz.com and the Letter of Intent issued ... fully executed Purchase Agreement. Charles R. ... proud to have Mr. David Pecoraro and ... in the private sector and developed a tremendous network ...
    (Date:7/25/2014)... Maine, July 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... the second quarter of 2014 increased 11% versus the ... 1 for the second quarter of 2014 versus ... for changes in distributor inventory 2 . Earnings per ... 2014 increased 11% from the prior year period to ...
    Breaking Medicine Technology:GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33
    ... As Florida legislators seek ways to reduce Medicaid spending, ... from the archaic fee-for-service model to the more efficient model ... A recent study finds that the program could ... of its pharmacy benefits more like those in Medicare and ...
    ... BALTIMORE, March 10, 2011 Remedi SeniorCare®, which ... is revolutionizing the long-term care (LTC) pharmacy industry ... dose medication administration system enabled by fully automated ... expand its existing operations in Maryland and the ...
    Cached Medicine Technology:Budget Solution? Modernizing Medicaid Pharmacy Could Save Florida $473 Million 2Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 2Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 3Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 4
    (Date:7/27/2014)... Zensah®, the leader in compression technology and ... wrist support . The wrist support features an adjustable ... Lateral and Medial Epicondylitis, more commonly referred to as tennis ... is inflammation of the tendons attached to the outside of ... the muscles that work the wrist and fingers turn into ...
    (Date:7/27/2014)... MI (PRWEB) July 27, 2014 Manufacturers ... public with organic ways to achieve a younger appearance. ... cream buyer's guide to help men and women explore ... , The details that are presented in the posted ... of price information for consumers. On drawback to some ...
    (Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
    (Date:7/27/2014)... The report, “Glass Fiber & Glass Fiber ... By Manufacturing Process, By Application (Transportation, Construction, Electrical ... Global Trends & Forecast to 2019”, defines and ... analysis and forecast by value and volume. , ... spread through 347 slides and in-depth TOC on ...
    (Date:7/27/2014)... medication to treat asthma and pneumonia can become ineffective. , ... drugs widely used to treat lung diseases work with the ... is caused by an infection, affects around 1 in 1000 ... children, the elderly, smokers and those with an underlying health ... UK are affected by asthma and the NHS spends around ...
    Breaking Medicine News(10 mins):Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2
    ... Medicine identify yet another reason to indulge in a vegetarian ... a critical role in the development// of lightweight, yet healthy ... to have a low bone mass. ,The study ... 33 and 85 years, under a strict vegan diet, devoid ...
    ... made by family of patients at Swansea psychiatric hospital, it is ... linked with the closure of kitchens at Cefn Coed Hospital//. ... following the closure of the kitchens at Cefn Coed Hospital. , ... the Swansea NHS Trust to what it called a "cook chill" ...
    ... Harvey Lodish and his post-doc Chengcheng Zhang from Whitehead Institute ... growth factors// which enriches and increases the number of stem ... the recipient. ,Stem cell therapy as shown ... is very high and it requires isolating large number of ...
    ... in supply of blood to the brain cells, which occurs due ... by a blocked artery and Hemorrhagic stroke is caused due to ... stopping of blood to the brain cells can lead to dead ... the survival of the stroke patients depend upon the severity of ...
    ... novel method which can aid in the multiplication of ... has been discovered.// This finding could eventually pave way ... gene therapy techniques. ,The use of adult ... it is associated with less ethical concerns and surpasses ...
    ... Schering, has obtained promising results in the development of ... which comes almost 45 years after Schering developed the ... the form of an implanted hormonal capsule and an ... is headed by a slightly-built 53-year-old woman, Professor Ursula-Friederike ...
    Cached Medicine News:Health News:Raw Vegan Diet Promises Lightweight, Healthy Bones 2Health News:Novel Technique Can Enhance Stem Cell Multiplication By 30 Fold 2Health News:Male Contraceptive Pill Being Developed By Berlin Pharmaceutical 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: